Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high‐purity plasma‐derived factor X (pdFX) concentrate

Background Hereditary factor X (FX) deficiency (FXD) affects 1:500 000‐1:1 000 000 people worldwide. A novel, high‐purity plasma‐derived FX concentrate (pdFX) is available in the United States and European Union as replacement therapy for FXD, but data are scarce on pdFX use in children

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2018-11, Vol.24 (6), p.941-949
Hauptverfasser:	Liesner, R., Akanezi, C., Norton, M., Payne, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Child Child, Preschool Children clotting factor concentrate Coagulation factors Dose-Response Relationship, Drug efficacy Factor X - adverse effects Factor X - metabolism Factor X - pharmacokinetics Factor X - pharmacology factor X deficiency Factor X Deficiency - complications Female Hemorrhage - complications Hemorrhage - prevention & control Humans Infant Infant, Newborn Laboratories Male paediatric Pharmacokinetics Plasma - metabolism Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Hereditary factor X (FX) deficiency (FXD) affects 1:500 000‐1:1 000 000 people worldwide. A novel, high‐purity plasma‐derived FX concentrate (pdFX) is available in the United States and European Union as replacement therapy for FXD, but data are scarce on pdFX use in children
ISSN:	1351-8216 1365-2516
DOI:	10.1111/hae.13500